New Launch16 May 2026, 09:31 am
Dr. Reddy's Launches Generic Semaglutide Injection in Canada
AI Summary
Dr. Reddy's Laboratories Ltd. has launched its generic Semaglutide Injection in Canada, following the Notice of Compliance (NOC) received from Health Canada on April 28th, 2026. Dr. Reddy’s is among the first companies to introduce a generic Semaglutide Injection in the Canadian market. The injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus, to improve glycemic control in combination with diet and exercise. It is supplied as a sterile solution for subcutaneous injection in pre-filled pens.
Key Highlights
- Dr. Reddy's launches generic Semaglutide Injection in Canada after Health Canada approval.
- Canada is the first G7 country to authorize generic Semaglutide Injection.
- The injection is for treating type 2 diabetes in adults, improving glycemic control.
- Semaglutide Injection is available in 2 mg/pen and 4 mg/pen strengths.
- This launch builds on the momentum of their recent launch in India under the brand name Obeda®.